Summary:
To evaluate the efficacy of multiple dose levels of NYX--2925 versus placebo in treating the neuropathic pain associated with Diabetic Peripheral Neuropathy.
Qualified Participants Must:
• Have type 2 Diabetes
•
Be between the ages of 18-70
•
Hemoglobin A1c (HbA1c) less than or equal to 11%
•
Have diabetic peripheral neuropathy, of symmetrical nature in the lower extremities for more than 6 months to 10 years.
Qualified Participants May Receive:
May be compensated for their time and travel.